Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$254,199.00
Dec 9, 2024
For-profit organization
AAV packaging cell line generation.
1024275
The project aims to further develop the D19 clone into a user-friendly cell line for producing AAV vectors, enhancing supply for laboratories working on AAV-based gene therapies. The D19 cell line was generated by NRC from suspension and serum-free media-adapted HEK293SF cells. Using lentiviral vectors, this parental cell line was modified to integrate into its genome a gene expression regulation system induced by the addition of cumate and coumermycin to express AAV Rep proteins (Rep40 and Rep68).
$278,187.00
Dec 6, 2024
Not-for-profit organization or charity
Voices of ManTalk: Building Capacity and Sharing Knowledge about Working with Marginalized Victims of Sexual Abuse
13273119
ManTalk 2.0 is a therapy program for male-identified survivors of sexual abuse.
$75,000.00
Dec 1, 2024
For-profit organization
Feasibility and Integration of AI-Assisted Therapy for Addiction Recovery
1024637
This project explores the feasibility of AI-assisted therapy for addiction recovery for initiating the development of AlchemistOne's go-to-market version.
$15,000.00
Dec 1, 2024
For-profit organization
Develop digital adoption plan
$15,000.00
Nov 20, 2024
For-profit organization
Develop digital adoption plan
$484,000.00
Nov 1, 2024
Academia
ARIADNE: platform for Accelerated and pRecisIon pAndemic Diagnostics and iNfection hEalth
1024053
It integrates NRC's microfluidic technology with novel gene circuit-based molecular sensors, facilitated by machine learning algorithms for biomarker refinement.
$95,150.00
Nov 1, 2024
Academia
The Development of a Functional, CGT-Relevant Cas12a crRNA Arrayed Knockout Library
1025925
This proposal seeks to design and to construct a functional, CGT-relevant Cas12a crRNA arrayed library containing ~ 10,000 sequenced crRNA, which will then be available to the greater Canadian Cell and Gene Therapy community. To do so, we will leverage the expertise developed over the last few years in optimizing the design of Cas12a crRNA and the production of two PoC 96-well plate to ensure the feasibility in producing a larger-size library.
$286,532.00
Nov 1, 2024
Academia
Process Development for GMP-Grade Anti-BCMA CAR-NK Cell Manufacturing
1026523
Chimeric Antigen Receptor-T (CAR-T) therapy is a revolutionary treatment in which T-cells are genetically engineered to enhance their ability to target and destroy cancerous cells. While CAR-T therapy is highly effective in hematological tumors, it is also very expensive, is associated with significant toxicities like Cytokine Release Syndrome (CRS) and Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS), and has made little progress outside of blood cancers. To overcome these limitations, we are developing CAR-NK cells as an off-the-shelf therapy. Our preclinical studies have clearly demonstrated the potential of anti-BCMA CAR-NK cells in treating multiple myeloma.
$75,000.00
Nov 1, 2024
For-profit organization
Pre-clinical R and D of a novel non-opioid drug for the treatment of chronic pain
1024974
The company has validated its’ proprietary compounds on this new pain therapy target and the current project will concentrate on the chemical synthesis and biological validation studies to identify and develop back-up compounds as a risk mitigation strategy for the lead compounds currently in development.
$75,000.00
Nov 1, 2024
For-profit organization
MNC Collab - FOCUS2024 - Fusogenix Formulation Development for Safe and Potent Delivery of Nucleic Acid Cargoes in the Eye
1024027
As part of Multinational Corporate Collaboration Program, the project “Fusogenix Formulation Development for Safe and Potent Delivery of Nucleic Acid Cargoes in the Eye” will focus on the evaluation of the safety and effectiveness of a gene, encoded in partner mRNA, in correcting an ophthalmological disease when delivered to the eye using Firm's proprietary drug delivery technology platform.